Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
British National Formulary (BNF) (69th ed.)
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Data on perioperative complications (pulmonary aspiration) and LOS were collected from medical records
An additional 202 articles were excluded for the following reasons: irrelevant study population (n=60), unrelated interventions (n=90), insufficient or incomplete data (n=52), and language limitations (non-English)
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
